Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-859 · 1 trial · 1 indication
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.
Cmax of ABBV-859
Beta of ABBV-859
t1/2 of ABBV-859
AUCt of ABBV-859
AUCinf of ABBV-859
CL/F of ABBV-859
Incidence and concentration of anti-drug antibodies.
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose A, or the Placebo equivalent, on Study Day 1 |
| Group 2 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose B, or the Placebo equivalent, on Study Day 1 |
| Group 3 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose C, or the Placebo equivalent, on Study Day 1 |
| Group 4 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose D, or the Placebo equivalent, on Study Day 1 |
| Group 5 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose E, or the Placebo equivalent, on Study Day 1 |
| Group 6 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose F, or the Placebo equivalent, on Study Day 1 |
| Group 7 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose G, or the Placebo equivalent, on Study Day 1 |
| Group 8 | EXPERIMENTAL | Participants will receive either ABBV-859 single Dose H, or the Placebo equivalent, on Study Day 1 |
| Name | Type | Description |
|---|---|---|
| ABBV-859 | DRUG | Oral Tablet |
| Placebo for ABBV-859 | DRUG | Oral Tablet |
Inclusion Criteria: * Participants must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures. * Body Mass Index (BMI) is \>= 18.0 to \<= 32 kg/m2 after...
ABBV-859 is an investigational small molecule drug being developed by AbbVie Inc. It is currently in Phase 1 clinical development and has not been approved by the FDA. Its first human study is a single ascending dose trial in healthy adult volunteers, which is designed to assess safety, tolerability, and how the drug moves through the body.
ABBV-859 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the ongoing Phase 1 study of the compound.
ABBV-859 is in Phase 1 clinical development. It is an investigational drug and is not FDA approved. The only registered trial of ABBV-859 is a Phase 1 study, and no later-phase trials have been registered.
ABBV-859 is being studied in one clinical trial, NCT07736638, titled A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants. The trial is currently recruiting, is randomized, double-blind, and controlled, and plans to enroll 64 healthy adult volunteers in the United States.
ABBV-859 is not yet used to treat any condition. It is an investigational drug in Phase 1 testing, and its only registered trial enrolls healthy adult volunteers rather than patients with a specific disease. No approved indication has been established for ABBV-859.